表紙
市場調査レポート

英国における骨粗しょう症向け医薬品の予測と市場分析

PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 267077
出版日 ページ情報 英文 128 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
英国における骨粗しょう症向け医薬品の予測と市場分析 PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022
出版日: 2013年02月28日 ページ情報: 英文 128 Pages
概要

当レポートでは、英国の骨粗しょう症市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報、主要薬剤の売上予測、主要イベントの影響分析、市場促進要因・抑制要因などを検証して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
    • リスク因子
    • 生活の質(QOL)
  • 症状

第4章 疾病管理

  • 治療の概要
    • 診断・照会
    • 治療ガイドライン
    • 疾病管理
  • 英国
    • 診断
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業評価
  • 製品プロファイル:主要ブランド

第6章 機会・アンメットニーズ

  • 概要
  • アンメットニーズ
    • 病気の認識・初期の診断
    • 患者コンプライアンス
    • 効能
    • 安全性
    • 治療コスト
    • 早期の治療介入
  • アンメットニーズ格差分析
  • 機会1:二重作用治療
  • 機会2:骨粗しょう症予防治療
  • 機会3:服薬・投与

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 市場展望

  • 英国
    • 予測
    • 主なイベント
    • 発展因子・発展阻害因子

第9章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1052CFR

Abstract

PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

The large dip in sales caused by these expiries is offset by pipeline product launches over the forecast period, with three of these being potential blockbuster drugs. This next generation of drugs typically consists of biologics and will be higher priced than the drugs losing patent protection in the first half of the forecast period.

Scope

  • Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the UK from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the UK Osteoporosis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the UK

TOC

1 Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 7
  • 1.2 List of Figures 9

2 Introduction 10

  • 2.1 Catalyst 10
  • 2.2 Related Reports 10

3 Disease Overview 13

  • 3.1 Etiology and Pathophysiology 13
    • 3.1.1 Etiology 13
    • 3.1.2 Pathophysiology 16
    • 3.1.3 Risk Factors 17
    • 3.1.4 Quality of Life 17
  • 3.2 Symptoms 18

4 Disease Management 19

  • 4.1 Treatment Overview 19
    • 4.1.1 Diagnosis and Referral 19
    • 4.1.2 Treatment Guidelines 20
    • 4.1.3 Disease Management 21
  • 4.2 United Kingdom 24
    • 4.2.1 Diagnosis 24
    • 4.2.2 Clinical Practice 25

5 Competitive Assessment 26

  • 5.1 Overview 26
  • 5.2 Strategic Competitor Assessment 26
  • 5.3 Product Profiles - Major Brands 30
    • 5.3.1 Actonel (risedronate sodium) 30
    • 5.3.2 Evista (raloxifene hydrochloride) 33
    • 5.3.3 Reclast (zolendronic acid) 36
    • 5.3.4 Forteo (teriparatide) 39
    • 5.3.5 Prolia (denosumab) 43
    • 5.3.6 Protelos (strontium ranelate) 46
    • 5.3.7 Miacalcin and Fortical (calcitonin-salmon) 49
    • 5.3.8 Viviant/Conbriza (bazedoxifene) 52
    • 5.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 55
    • 5.3.10 Alendronate sodium 57
    • 5.3.11 Ibandronate 59

6 Opportunity and Unmet Need 60

  • 6.1 Overview 60
  • 6.2 Unmet Needs 60
    • 6.2.1 Disease Awareness and Early Diagnosis 60
    • 6.2.2 Patient Compliance 61
    • 6.2.3 Efficacy 62
    • 6.2.4 Safety 62
    • 6.2.5 Treatment Cost 63
    • 6.2.6 Earlier Intervention 63
  • 6.3 Unmet Needs Gap Analysis 64
  • 6.4 Opportunity 1: Dual-Action Therapies 65
  • 6.5 Opportunity 2: Osteoporosis Prevention Therapies 66
  • 6.6 Opportunity 3: Dosing and Administration 67

7 Pipeline Assessment 68

  • 7.1 Overview 68
  • 7.2 Promising Drugs in Clinical Development 69
    • 7.2.1 Aprela (bazedoxifene and conjugated estrogens) 70
    • 7.2.2 Romosozumab (AMG-785) 76
    • 7.2.3 Odanacatib 81
    • 7.2.4 BA-058 86
    • 7.2.5 PTH(1-31)NH2 90
    • 7.2.6 Ostora (recombinant salmon calcitonin) 94

8 Market Outlook 100

  • 8.1 United Kingdom 100
    • 8.1.1 Forecast 100
    • 8.1.2 Key Events 104
    • 8.1.3 Drivers and Barriers 104

9 Appendix 107

  • 9.1 Bibliography 107
  • 9.2 Abbreviations 114
  • 9.3 Methodology 116
  • 9.4 Forecasting Methodology 116
    • 9.4.1 Diagnosed Osteoporosis Patients 117
    • 9.4.2 Percent Drug-Treated Patients 117
    • 9.4.3 Drugs Included in Each Therapeutic Class 117
    • 9.4.4 Launch and Patent Expiry Dates 118
    • 9.4.5 General Pricing Assumptions 119
    • 9.4.6 Individual Drug Assumptions 119
    • 9.4.7 Generic Erosion 124
    • 9.4.8 Pricing of Pipeline Agents 124
  • 9.5 Physicians and Specialists Included in this Study 125
    • 9.5.1 About the Authors 126
    • 9.5.2 Global Head of Healthcare 127
  • 9.6 About GlobalData 128
  • 9.7 Contact Us 128
  • 9.8 Disclaimer 128

List of Tables

1.1 List of Tables

  • Table 1: Etiology of Primary Osteoporosis 13
  • Table 2: Etiology of Secondary Osteoporosis 15
  • Table 3: Symptoms of Osteoporosis 18
  • Table 4: Diagnostic Tests for Osteoporosis 19
  • Table 5: T-Score Ranges for Determination of BMD 20
  • Table 6: Treatment Guidelines for Osteoporosis 21
  • Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 22
  • Table 8: Leading Treatments for Osteoporosis, 2012 29
  • Table 9: Product Profile - Actonel 31
  • Table 10: Actonel SWOT Analysis, 2012 32
  • Table 11: Product Profile - Evista 34
  • Table 12: Evista SWOT Analysis, 2012 35
  • Table 13: Product Profile - Reclast 37
  • Table 14: Reclast SWOT Analysis, 2012 38
  • Table 15: Product Profile - Forteo 40
  • Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 41
  • Table 17: Forteo SWOT Analysis, 2012 42
  • Table 18: Product Profile - Prolia 43
  • Table 19: Prolia SWOT Analysis, 2012 45
  • Table 20: Product Profile - Protelos 46
  • Table 21: Protelos SWOT Analysis, 2012 47
  • Table 22: Product Profile - Miacalcin and Fortical Nasal Spray 50
  • Table 23: Adverse Events with Miacalcin Nasal Spray 50
  • Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 51
  • Table 25: Product Profile - Viviant/Conbriza 53
  • Table 26: Viviant/Conbriza SWOT Analysis, 2012 54
  • Table 27: Product Profile - Recalbon/Bonoteo 55
  • Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 56
  • Table 29: Overall Unmet Needs - Current Level of Attainment 60
  • Table 30: Clinical Unmet Needs - Gap Analysis, 2012 64
  • Table 31: Osteoporosis - Pipeline, 2012 69
  • Table 32: Comparison of Therapeutic Classes in Development for Osteoporosis, 2012 69
  • Table 33: Product Profile - Aprela 71
  • Table 34: Aprela SWOT Analysis, 2012 75
  • Table 35: Product Profile - Romosozumab 76
  • Table 36: Romosozumab SWOT Analysis, 2012 80
  • Table 37: Product Profile - Odanacatib 81
  • Table 38: Odanacatib SWOT Analysis, 2012 85
  • Table 39: Product Profile - BA-058 86
  • Table 40: BA-058 SWOT Analysis, 2012 89
  • Table 41: Product Profile - PTH(1-31)NH2 91
  • Table 42: PTH(1-31)NH2 SWOT Analysis, 2012 93
  • Table 43: Product Profile - Ostora 95
  • Table 44: Ostora SWOT Analysis, 2012 98
  • Table 45: UK Sales Forecasts ($m) for Osteoporosis, 2012-2022 102
  • Table 46: Key Events Impacting Sales for Osteoporosis in the UK, 2012-2022 104
  • Table 47: Osteoporosis Market - Drivers and Barriers in the United Kingdom, 2012-2022 104
  • Table 48: Key Launch Dates 118
  • Table 49: Key Patent Expiries 118
  • Table 50: Number of High-Prescribing Physicians Surveyed 125

List of Figures

1.2 List of Figures

  • Figure 1: Company Portfolio Gap Analysis in Osteoporosis, 2012-2022 70
  • Figure 2: Sales for Osteoporosis in the UK by Drug Class, 2012-2022 103
Back to Top